The Fly

AmerisourceBergen price target raised to $190 from $184 at UBS

UBS analyst Kevin Caliendo raised the firm’s price target on AmerisourceBergen (ABC) to $190 from $184 and keeps a Buy rating on the shares as part of a broader research note on pharma distributors. The analyst contends that Pharma distribution is a relative safe haven while noting "stable" Rx trends and positive channel checks around brand and generic drug inflation. AmerisourceBergen is "best positioned for outperformance" as the stock is is relatively de-risked with upside possible from easing currency headwinds and the timing of Walgreens Boots Alliance (WBA) repurchases, the firm adds.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on ABC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More